Journal
ADDICTION
Volume 107, Issue -, Pages 63-73Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1360-0443.2012.04040.x
Keywords
Full-term infant; neonatal abstinence syndrome; neurobehavior; NICU Network Neurobehavioral Scale (NNNS); opioid exposed newborn
Categories
Funding
- National Institute on Drug Abuse (NIDA)
- National Institute on Drug Abuse (NIDA), Brown University [R01 DA 015778]
- National Institute on Drug Abuse (NIDA), Johns Hopkins University [R01 DA 015764]
- National Institute on Drug Abuse (NIDA), Medical University of Vienna [R01 DA 018417]
- National Institute on Drug Abuse (NIDA), Thomas Jefferson University [R01 DA 015738]
- National Institute on Drug Abuse (NIDA), University of Toronto [R01 DA 015741]
- National Institute on Drug Abuse (NIDA), University of Vermont [R01 DA 018410, M01 RR 109]
- National Institute on Drug Abuse (NIDA), Vanderbilt University [R01 DA 017513, M01 RR 00095]
- National Institute on Drug Abuse (NIDA), Wayne State University [R01 DA 15832]
- Reckitt Benckiser
- Schering Plough
- Schering Canada
- Government of Ontario
Ask authors/readers for more resources
Aim To determine the effects of in utero exposure to methadone or buprenorphine on infant neurobehavior. Design Three sites from the Maternal Opioid Treatment: Human Experimental Research (MOTHER) study, a double-blind, double-dummy, randomized clinical trial participated in this substudy. Setting Medical Centers that provided comprehensive maternal care to opioid-dependent pregnant women in Baltimore, MD, Providence, RI and Vienna, Austria. Participants Thirty-nine full-term infants. Measurements The Neonatal Intensive Care Unit (NICU) Network Neurobehavioral Scale (NNNS) was administered to a subgroup of infants on postpartum days 3, 5, 7, 10, 1415 and 2830. Findings While neurobehavior improved for both medication conditions over time, infants exposed in utero to buprenorphine exhibited fewer stress-abstinence signs (P<0.001), were less excitable (P<0.001) and less over-aroused (P<0.01), exhibited less hypertonia (P<0.007), had better self-regulation (P<0.04) and required less handling (P<0.001) to maintain a quiet alert state relative to in utero methadone-exposed infants. Infants who were older when they began morphine treatment for withdrawal had higher self-regulation scores (P<0.01), and demonstrated the least amount of excitability (P<0.02) and hypertonia (P<0.02) on average. Quality of movement was correlated negatively with peak NAS score (P<0.01), number of days treated with morphine for NAS (P<0.01) and total amount of morphine received (P<0.03). Excitability scores were related positively to total morphine dose (P<0.03). Conclusion While neurobehavior improves during the first month of postnatal life for in utero agonist medication-exposed neonates, buprenorphine exposure results in superior neurobehavioral scores and less severe withdrawal than does methadone exposure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available